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Functional Analysis of LDLR (Low-Density 
Lipoprotein Receptor) Variants in Patient 
Lymphocytes to Assess the Effect of Evinacumab 
in Homozygous Familial Hypercholesterolemia 
Patients With a Spectrum of LDLR Activity
Poulabi Banerjee, Kuo-Chen Chan, Michel Tarabocchia, Asier Benito-Vicente, Ana C. Alves, Kepa B. Uribe, Mafalda Bourbon,  
Paul J. Skiba, Robert Pordy, Daniel A. Gipe,* Daniel Gaudet, Cesar Martin
OBJECTIVE: Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein 
receptor) mutations. Homozygous familial hypercholesterolemia is characterized by markedly elevated LDL-C (low-density 
lipoprotein cholesterol) levels and an extremely high risk of premature atherosclerotic cardiovascular disease. A phase 2, 
proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 
(angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial 
hypercholesterolemia and was well tolerated. The aim of this study was to analyze the effects of evinacumab on LDLR activity 
in lymphocytes purified from patients in the proof-of-concept study.
APPROACH AND RESULTS: LDLR activity was assessed in patient lymphocytes before and after treatment with evinacumab and versus 
lymphocytes carrying wild-type LDLR, and also in an LDLR-defective Chinese hamster ovary cell line (CHO-ldlA7) transfected 
with plasmids encoding the LDLR variants. Overall mean peak reduction in LDL-C with evinacumab was −58±18%, occurring 
between Week 4 and Week 12. Mutations identified in the 9 patients were shown to be pathogenic, with loss of LDLR activity 
versus wild type. Two of the LDLR variants, p.(Cys681*) and p.(Ala627Profs*38), were class 2 type mutations that are retained in 
the endoplasmic reticulum. Six variants were class 3 type mutations with impaired LDL-C binding activity: p.(Trp87Gly), occurring 
in 2 patients, p.(Gln254Pro), p.(Ser177Leu), p.(Gly335Val), and p.(Ser306Leu). Evinacumab had no effect on LDLR activity.
CONCLUSIONS: These results suggest that evinacumab is effective for lowering LDL-C in patients with homozygous familial 
hypercholesterolemia, and the inhibition of ANGPTL3 in humans lowers LDL-C in a mechanism independent of the LDLR.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: hypercholesterolemia ◼ lipoproteins ◼ mutations ◼ proof of concept study ◼ rare disease
Familial hypercholesterolemia (FH; MIM#143890) is an autosomal dominant disorder causing prema-ture coronary heart disease that is characterized by increased plasma LDL-C (low-density lipoprotein cholesterol), tendon xanthomas, and deposits of cho-lesterol in peripheral tissues leading to accelerated 
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atherosclerosis.1,2 In 95% of the cases, FH is because 
of mutations in the LDLR (low-density lipoprotein recep-
tor; MIM# 606945) gene,3 which is responsible for 
the uptake of LDL particles into cells.4 Historically, FH 
was reported to have a homozygous frequency of 1 in 
1 000 000,5 although the heterozygous frequency has 
recently been estimated as high as 1 in ≈200 (based on 
Dutch Lipid Clinic Network criteria) or 1 in 244 for FH 
based on molecular criteria in some northern European 
populations, and up to 1 in 80 in some founder popula-
tions such as French Canada,6 suggesting that the fre-
quency of homozygous FH (HoFH) is in the region of 
1:600 000 to 1:300 000.1 Although there is wide phe-
notypic variability among HoFH patients,7 LDL-C values 
in those who are untreated usually reach concentrations 
>500 mg/dL (13 mmol/L), leading to premature cardio-
vascular events1 and premature death.8
Currently, >2500 different variants have been 
described on the LDLR gene but not all of them are 
pathogenic (ie, FH-causing).9 The nature and location of 
the mutations within the LDLR gene determine the activ-
ity of the receptor and, therefore, mutations have been 
divided into 5 classes:10 Class 1: no detectable LDLR 
synthesis; Class 2: defective LDLR transport from the 
endoplasmic reticulum; Class 3: impaired LDL to LDLR 
binding; Class 4: no LDLR/LDL internalization because 
of defective clustering in clathrin-coated pits; and Class 
5: no LDLR recycling. Recently, a sixth class has been 
proposed that includes mutants that are incorrectly 
inserted in the cell membrane.11,12 Among LDLR defec-
tive mutations, residual LDLR activity can vary in the 
range of 2% to 80%; therefore, the treatment strategy 
must be evaluated to achieve the highest effectiveness.
The currently available pharmacological treatments, 
which include statins, ezetimibe, mipomersen, lomitapide, 
and evolocumab, are insufficient to bring HoFH patients 
to optimal LDL-C levels.1,13,14 It has been shown that 
evolocumab, a PCSK9 (proprotein convertase subtilisin/
kexin type 9) inhibitor, promotes a 20% to 30% mean 
reduction in LDL-C in HoFH patients.15–17 However, 
the activity of the LDLR is reduced to variable degrees 
depending on class type mutation, and evolocumab does 
not lower LDL-C in HoFH patients with class 1 muta-
tions or extreme LDLR mutations with low residual activ-
ity or binding capacity.15–19
Studies have shown that the ANGPTL3 (angiopoietin-
like 3 protein) affects lipoprotein metabolism by inhibit-
ing LPL (lipoprotein lipase), which hydrolyzes triglycerides 
from chylomicrons and low-density lipoproteins.20 Low 
plasma triglyceride and high-density lipoprotein choles-
terol levels have been associated with ANGPTL3 loss-of-
function variants because of a lack of LPL inhibition.21,22 In 
addition, ANGPTL3 inhibits endothelial lipase, which cata-
lyzes the hydrolysis of high-density lipoprotein phospholip-
ids and facilitates the clearance of high-density lipoprotein 
from the circulation.20 Recently, evinacumab, a fully human 
ANGPTL3-blocking antibody generated by VelocImmune 
technology, was found to lower cholesterol and triglyceride 
levels in healthy human volunteers.23 Furthermore, admin-
istration of evinacumab to 9 HoFH patients in an open-
label, phase 2, proof-of-concept study resulted in further 
substantial reductions in LDL-C levels on top of those 
achieved with stable, aggressive lipid-lowering therapy.19
The aim of this study was to analyze the effects of evi-
nacumab on the activity of LDLR in lymphocytes purified 
from the HoFH patients included in the proof-of-concept 
study, before and after treatment with the antibody. Enrolled 
patients had a documented history of HoFH diagnosis with 
mutation(s) in both LDLR alleles. LDLR activity was also 
assessed in a LDLR-defective Chinese hamster ovary 
(CHO) cell line (CHO-ldlA7) transfected with plasmids 
Nonstandard Abbreviations and Acronyms
ANGPTL3 angiopoietin-like 3 protein
CHO Chinese hamster ovary
FITC fluorescein isothiocyanate
FH familial hypercholesterolemia
HoFH homozygous FH
LDL-C low-density lipoprotein cholesterol
LDLR low-density lipoprotein receptor
LLT lipid-lowering therapy
LPL lipoprotein lipase
PCSK9  proprotein convertase subtilisin/kexin 
type 9
wt wild type
Highlights
• We analyzed the effect of ANGPTL3 (angiopoi-
etin-like 3 protein) inhibition on LDLR (low-density 
lipoprotein receptor) activity in lymphocytes from 
homozygous familial hypercholesterolemia patients 
(n=9) who received evinacumab in a proof-of-con-
cept study.
• LDL-cholesterol was reduced with evinacumab in all 
patients, with mean peak reduction of −58±18% 
occurring between Weeks 4 and 12.
• Mutations identified from the patients were shown to 
have loss of LDLR activity versus wild-type because 
of either defective endoplasmic reticulum transport 
or impaired LDL-cholesterol binding activity.
• Evinacumab had no functional effect on LDLR 
activity.
• ANGPTL3 inhibition lowers LDL-cholesterol inde-
pendently of LDLR, suggesting that evinacumab 
may be effective for lowering LDL-cholesterol in 
patients with homozygous familial hypercholesterol-
emia who are otherwise difficult to treat.
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encoding the LDLR variants. From these analyses, we 
aimed to confirm that evinacumab has an LDLR-indepen-
dent mechanism by assessing the level of LDLR expres-
sion, and LDL binding and uptake, in the LDLR variants.
MATERIALS AND METHODS
Qualified researchers may request access to study documents 
(including the clinical study report, study protocol with any 
amendments, blank case report form, and statistical analysis 
plan) that support the methods and findings reported in this 
article. Individual anonymized participant data will be consid-
ered for sharing once the indication has been approved by a 
regulatory body, if there is legal authority to share the data and 
there is not a reasonable likelihood of participant reidentifica-
tion. Submit requests to https://errs.regeneron.com/external.
Subject Selection and Treatment
Patient selection for the phase 2, proof-of-concept 
study (NCT02265952) was carried out by Regeneron 
Pharmaceuticals, Inc, details of which have been described 
previously.19 Briefly, male and female patients at least 18 years 
of age with an HoFH diagnosis by (1) documented FH-causing 
mutation(s) in both LDLR or APOB alleles, (2) documented 
presence of double heterozygous variants in LDLR, APOB, 
and PCSK9, or (3) documented skin fibroblast LDLR activ-
ity <20% of normal were eligible for inclusion in the study; 
however, only patients with HoFH and mutations in both LDLR 
alleles were enrolled. They were also required to be on stable, 
aggressive lipid-lowering therapy for at least 4 weeks (includ-
ing statins, fibrates, ezetimibe, lomitapide, PCSK9 inhibitors, 
and portacaval shunt), and to have not undergone lipid apher-
esis within 4 weeks before the screening visit. All patients pro-
vided written informed consent.
Two control subjects, previously described,24,25 were used 
for internal method validation. The first was a heterozygous FH 
patient carrying a mutation in the LDLR gene that produces 
a defective binding protein because the mRNA contains an 
in-frame deletion of exons 3 and 4, c.(191-?_694+?del). The 
second was a heterozygous FH patient carrying the c.261G>A, 
p.(Trp87*) LDLR variant, a null allele mutant that does not pro-
duce LDLR.
Patients received evinacumab 250 mg administered subcu-
taneously in the abdominal area at baseline, and then a single 
15 mg/kg intravenous dose 2 weeks later. Of the 9 patients 
included in the phase 2 study, 2 received 4 additional doses of 
evinacumab 450 mg subcutaneously at weeks 12 to 15.
Isolation and Culture of T-Lymphocytes
Patient blood samples were collected on the baseline visit, and 
peripheral blood lymphocytes from patient blood samples were 
isolated from Vacutainer CPT (BD Biosciences, CA) tubes fol-
lowing the manufacturer’s instructions. Cells were then cul-
tured at 37°C in 5% CO2 at a concentration of 2×10
5 cells/
mL in medium supplemented with lipoprotein-deficient serum, 
antibiotics, and antimycotics. Anti-CD3/CD28 beads (Dynal 
Biotech, ThermoFisher Scientific, Norway; 2×105 beads/mL) 
were also added to obtain suitable T-cell activation to upregu-
late the LDLR.
Lipoprotein Isolation
Lipoproteins were isolated from blood samples from normo-
cholesterolemic controls in a 2-step centrifugation procedure. 
Briefly, blood was collected in ethylenediaminetetraacetic acid 
tubes and plasma was separated by centrifugation for 30 min-
utes, at 12 000×g at 4°C. Blood plasma LDL (1.019–1.050 g/
mL) was isolated by density ultracentrifugation, adjusting the 
density of plasma to 1.21 g/mL by the addition of potassium 
bromide, and obtaining 2 phases with PBS buffer. The sample 
was centrifuged at 244 500×g for 19 hours 30 minutes at 4°C. 
The band corresponding to LDL was recovered carefully, stored 
at 4°C, and used within the next 4 to 5 days. Further analysis 
by complementary techniques of samples obtained with this 
procedure confirmed that the LDL purification was near purity.
Lipoprotein Labeling
LDL was labeled with fluorescein isothiocyanate (FITC), as 
previously described.10 Briefly, lipoproteins (1 mg/mL) in 0.1 M 
NaHCO3 (pH 9.0) were mixed with 10 µL/mL of FITC (2 mg/
mL in dimethyl sulfoxide). The mixture was gently mixed by slow 
rocking at room temperature for 2 hours. The unreacted dye 
was removed by gel filtration on a Sephadex G-25 mounted in 
a PD-10 desalting column (GE Healthcare, IL) equilibrated with 
PBS ethylenediaminetetraacetic acid-free buffer. All fractions 
were assayed for protein content with BSA as standard (Pierce 
BCA protein assay, Pierce, ThermoFisher Scientific, MA).
Quantification of LDLR Activity and Expression 
by Flow Cytometry in Lymphocytes
LDLR cell surface expression and LDLR activity (includ-
ing LDL binding capacity and LDL uptake) was determined 
by flow cytometry in lymphocytes. Lymphocytes were taken 
from patients before and after the patients were treated with 
evinacumab, and then the activity assays were performed. 
Lymphocytes were isolated using BD Vacutainer CPT Cell 
Preparation Tubes with Sodium Citrate (REF 362761, BD 
Biosciences, CA) following the manufacturer’s instructions. 
Lymphocytes (2×105 cells) were cultured for 72 hours in lipo-
protein-deficient serum and stimulated with anti-CD3/CD28 
beads to obtain a uniform fraction of lymphoblasts with a maxi-
mum upregulation of LDLR. Lymphoblasts are slightly bigger 
in size and can be more efficiently selected by flow cytometry 
for further analysis of LDLR activity. Cells were recovered and 
washed twice in PBS containing 1% BSA (PBS-1%BSA).
To determine LDLR expression, cells were fixed in 4% para-
formaldehyde for 10 minutes, blocked with PBS-1%BSA-5% 
fetal bovine serum incubated with a mouse anti-LDLR primary 
antibody (1:100; 2.5 mg/L; Progen Biotechnik GmbH, Germany; 
reagent details are given in Major Resources Table in the online-
only Data Supplement ) for 1 hour at room temperature, washed 
twice with PBS-1%BSA, and incubated with an Alexa Fluor 
488-conjugated goat anti-mouse secondary immunoglobulin G 
antibody (1:100; Invitrogen, Molecular Probes, CA).
To determine LDLR activity, cells were incubated for 2 hours 
with 20 µg/mL FITC-LDL at either 37°C (to determine LDLR 
uptake) or 4°C (to determine LDL-LDLR binding). After incuba-
tion with FITC-LDL, lymphoblasts were washed twice in PBS-
1%BSA, fixed in 4% paraformaldehyde for 10 minutes, and 
washed twice more with PBS-1%BSA.
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To determine the amount of internalized LDL, Trypan blue 
solution (Sigma-Aldrich, Germany) was added directly to the 
same samples above to a final concentration of 0.2%, which 
quenches the extracellular signal because of the noninternal-
ized LDLR-LDL complexes.26
Fluorescence intensities were measured by fluorescence-
activated cell sorting in a FACSCalibur Flow cytometer (BD 
Biosciences, CA) according to the manufacturer’s instructions. 
Stimulated lymphoblasts could be separated from the unstimu-
lated ones according to areas in flow cytometric analysis. For 
each sample, fluorescence of 10 000 events was acquired for 
data analysis and the results were expressed as the mean fluo-
rescence of activated gated cells, selected in a forward- versus 
side-scatter window. All measurements were performed in trip-
licate. Heterozygous lymphocytes carrying c.(191-?_694+?del) 
LDLR variant that produces a defective binding receptor, and 
also heterozygous lymphocytes carrying c.261G>A, p.(Trp87*) 
LDLR variant, were used as internal controls of the assay.
Site-Directed Mutagenesis
Among the LDLR variants carried by the 9 HoFH patients, the 
expression of point mutation and frameshift LDLR variants was 
determined in vitro. The mutations were introduced into the 
human LDLR cDNA (NM_000527.4), in the mammalian expres-
sion vector pcDNA3 under control of a SV40 promoter by oli-
gonucleotide site-directed mutagenesis using QuickChange 
Lightning mutagenesis kit (Agilent Technologies, CA), according 
to the manufacturer’s instructions. The oligonucleotides used to 
generate the plasmid carrying the LDLR variant under study 
were synthesized in vitro and subcloned using the restriction 
enzymes SacII and EcoRI. The presence of the desired nucleo-
tide alteration was confirmed by polymerase chain reaction and 
restriction enzyme digestion of the appropriate fragments and 
the integrity of the remaining LDLR cDNA sequence of the con-
struct was verified by direct sequence analysis.
CHO Cell Culture and Transfection
An LDLR-deficient CHO cell line ldlA7 (CHO-ldlA7) was cultured 
in Ham’s F-12 medium supplemented with 5% fetal bovine serum, 
2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 µg/mL 
streptomycin. CHO-ldlA7 cells were plated into 6- or 24-well cul-
ture plates and transfected with the plasmids carrying wild-type 
(wt) LDLR or c.259T>G, p.(Trp87Gly), c.2043C>A, p.(Cys681*), 
c.761A>C, p.(Gln254Pro), c.1878delA, p.(Ala627Profs*38), 
c.530C>T, p.(Ser177Leu), c.1004G>T, p.(Gly335Val), and 
c.917C>T, p.(Ser306Leu) LDLR variants using Lipofectamine 
LTX and Plus Reagent (Invitrogen, ThermoFisher Scientific, MA) 
according to the manufacturer’s instructions. Transfected cells 
were maintained in culture for 48 hours to achieve maximal 
LDLR expression.
Western Blot Analysis
LDLR expression in CHO-ldlA7 cells transfected with mutations 
of interest were analyzed by immunoblotting. Cell lysates were 
prepared, protein concentration determined, and fractionated 
by electrophoresis on 8.5% sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis for semiquantitative immunoblotting. 
Membranes were immunostained with rabbit polyclonal anti-
LDLR antibody (1:500; Cayman Chemical, MI) for 16 hours at 
4°C and anti-GAPDH (GAPDH) antibody (1:1000) (Santa Cruz 
Biotechnology, Inc, CA) for 1 hour at room temperature (anti-
bodies and washing buffer have 2 mmol/L CaCl2) and counter-
stained with a horseradish peroxidase-conjugated anti-rabbit 
antibody (GE Healthcare, Little Chalfont, United Kingdom). The 
signals were developed using SuperSignal West Dura Extended 
Substrate (Pierce Biotechnology, ThermoFisher Scientific, IL). 
ChemiDoc XRS (Bio-Rad, CA) was used to detect the signals, 
and Quantity One Basic 4.4.0 software (Bio-Rad) was used to 
quantify band intensities. The concentrations of the antibod-
ies were optimized to achieve low background and a linear 
dose-dependent increase in signal intensity. The relative band 
intensity for the mature form of LDLR protein expressed for the 
different constructs was calculated as the ratio between the 
LDLR 160 kDa band to that of GAPDH. c.261G>A, p.(Trp87*), 
a variant that is not expressed, and c.1285G>C, p.(Val429Leu), 
a variant that is only expressed into its nonmature form, were 
used as internal controls of the assay.
Quantification of LDLR Activity and Expression 
by Flow Cytometry in Transfected CHO-ldlA7 
Cells
LDLR activity (including LDLR cell surface expression, LDL 
binding capacity, and LDL uptake) was determined by flow 
cytometry in CHO-ldlA7 transfected cells with plasmids encod-
ing the LDLR variants. Transfected CHO-ldlA7 cells were 
grown in 24-well culture plates. Forty-eight hours after trans-
fection, cells were incubated for 2 hours with 20 µg/mL FITC-
LDL at either 37°C or 4°C, as described above for lymphocytes.
To determine LDLR cell surface expression by fluorescence-
activated cell sorting, transfected CHO-ldlA7 cells grown dur-
ing 48 hours were incubated with a mouse anti-LDLR primary 
antibody (1:100; Cayman Chemical, cat no.: 10007665) for 
1 hour at room temperature, then washed twice with PBS-
1%BSA and incubated with secondary antibody Alexa Fluor 
488-conjugated goat anti-mouse immunoglobulin G (1:100), 
as described above for lymphocytes.
Fluorescence intensities were measured in a FACSCalibur 
Flow cytometer as described above for lymphocytes, and all 
measurements were performed in triplicate.
Confocal Laser Scanning Microscopy
LDLR variants found in the HoFH patients were classified by 
mutation type using confocal laser scanning microscopy, based 
on analysis of LDLR cell surface expression, LDL-LDLR binding, 
and LDL uptake in LDLR-transfected CHO-ldlA7 cells. Briefly, 
cells were plated in coverslips and then transfected with the 
LDLR-containing plasmids and cultured for 48 hours at 37°C in 
5% CO2. The medium was then removed and coverslips washed 
twice with PBS-1%BSA. To determine LDLR expression, cells 
were incubated for 16 hours at 4°C with a mouse primary anti-
body anti-LDLR, washed, and then incubated for 1 hour at room 
temperature with a secondary antibody Alexa Fluor 488-conju-
gated goat anti-mouse immunoglobulin G. To determine LDL-
LDLR binding and LDL uptake, Dil-labeled lipoproteins (20 µg/
mL LDL) were added and cells were incubated for an additional 4 
hours at 4°C or 37°C, respectively. Cells were fixed with 4% para-
formaldehyde for 10 minutes, washed 3× with PBS-1%BSA, 
and permeabilized with 1% Triton X-100 for 30 minutes at room 
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temperature. Samples were then washed and blocked in PBS-
10% fetal bovine serum for 1 hour and washed in PBS-1%BSA 
3×. The samples were then incubated with the appropriate pri-
mary antibodies for 16 hours at 4°C followed by incubation with 
the appropriate fluorescent secondary antibodies. Subcellular 
colocalization of LDLR variants with the endoplasmic reticulum 
was determined by using a primary antibody that recognized the 
endoplasmic reticulum-specific marker calregulin and the appro-
priate fluorescent secondary antibody. Coverslips were mounted 
on a glass slide and samples were visualized using a confo-
cal microscope (Olympus IX 81, Tokyo, Japan), with sequential 
excitation and capture image acquisition with a digital camera 
(Axiocam NRc5, Zeiss, Jena, Germany). Images were processed 
with Fluoview v.50 software. Image analysis to quantify the fluo-
rescence intensities was accomplished using the public domain 
software ImageJ (available at http://rsb.info.nih.gov/ij) running on 
a standard PC. Cells transfected with the c.(191-?_694+?del) 
LDLR variant that produces a defective binding receptor were 
used as internal controls of the assay
Variant Classification
Variants were classified as recommended by the American 
College of Medical Genetics and Genomics,27 adapted for FH 
specifications.9
In Silico Prediction of the LDLR Variant Under 
Study
To predict the possible impact of amino acid substitutions on 
the structure and function of the LDLR, 4 different types of 
software were used: PhyloP (https://omictools.com/phylo-
genetic-p-values-tool), Polyphen-2 (http://genetics.bwh.har-
vard.edu/pph2), SIFT (http://sift.jcvi.org), and Mutation Taster 
(http://www.mutationtaster.org).
Statistical Analysis
All measurements were performed at least 3×, unless other-
wise stated, and results are presented as mean±SD. To confirm 
that the data were normally distributed, a Shapiro-Wilk test was 
performed. The null hypothesis was verified, indicating that the 
data were normally distributed. As the intention was to compare 
wt with each mutant, that is, comparison of 2 variables, Student 
t-tests were employed for analysis. A 2-tailed Student t test 
with a significance level of 0.05 was used to test for differ-
ences in LDLR activity between wt patient samples and each 
patient’s samples before and after treatment. In addition, the 
same statistical method applies to the comparisons in LDLR 
activity between before and after treatment administration for 
each variant. All statistical analyses were performed with the 
SPSS 25 (SPSS, Inc, Chicago, IL).
RESULTS
Patient Characteristics
Baseline characteristics, LDL-C levels, and genotypes 
of the 9 HoFH patients enrolled in the study are shown 
in the Table. There were 2 null homozygotes and 1 com-
pound heterozygote with 2 null alleles.
LDL-C Reduction in HoFH Patients After 
Evinacumab Treatment
Overall mean peak reduction in LDL-C with evinacumab 
was −58±18%, occurring between Week 4 and Week 
12, showing that ANGPTL3 inhibition substantially 
reduced LDL-C in all participants (Table).
Effect of Evinacumab Treatment on LDLR 
Activity Determined in Lymphocytes From HoFH 
Patients
The LDLR activity was assessed in isolated lymphocytes 
from 9 HoFH patients before and after treatment with 
evinacumab, as described in the Materials and Methods 
section. As shown in Figure 1, lymphocytes from the 
HoFH patients had reduced LDLR activity compared with 
lymphocytes carrying wt LDLR. Evinacumab treatment did 
not modify LDLR activity, indicating no functional effect 
on LDLR activity with evinacumab treatment (Figure 1). 
As shown in Figure 1A, LDLR expression was highly 
heterogeneous, ranging from values of nearly 100% to 
10%. However, both LDL binding and uptake values were 
reduced, ranging from ≈60% to 10% both before and 
after evinacumab treatment (Figure 1B and 1C).
Expression of LDLR Variants in CHO-ldlA7 Cells
CHO-ldlA7 cells were transfected with plasmids carry-
ing wt LDLR or c.259T>G, p.(Trp87Gly); c.2043C>A, 
p.(Cys681*); c.761A>C, p.(Gln254Pro); c.1878del, 
p.(Ala627Profs*38); c.530C>T, p.(Ser177Leu); 
c.1004G>T, p.(Gly335Val); and c.917C>T, p.(Ser306Leu) 
LDLR variants. LDLR expression in cells with trans-
fected mutants and wt LDLR was analyzed by immu-
noblotting as described in the Materials and Methods 
section. For internal controls of the assay, 2 mutants, 
c.261G>A, p.(Trp87*), a variant that is not expressed, 
and c.1285G>C, p.(Val429Leu), a variant that is only 
expressed in its nonmature form, were used. As shown 
in Figure 2A (upper panel), expression of p.(Trp87Gly), 
p.(Gln254Pro), p.(Ser306Leu), and p.(Gly335Val) LDLR 
variants is similar to the expression of wt LDLR. Equal 
loading of protein was confirmed by membrane stripping 
and analysis of cytosolic GAPDH protein (Figure 2A, 
lower). The extent of protein expression was deter-
mined by quantitative densitometric analysis (Figure 2B). 
On the contrary, and as expected due to the nature 
of the variants, p.(Cys681*) and p.(Ala627Profs*38) 
were expressed as nonmature proteins with a smaller 
size (Figure 2C, upper). Figure 2C also shows that the 
expression of the mature LDLR protein p.(Ser177Leu) 
is less efficient compared with the mature wt LDLR 
control. The extent of protein expression in p.(Cys681*), 
p.(Ala627Profs*38), and p.(Ser177Leu) was determined 
by quantitative densitometric analysis (Figure 2D).
D
ow
nloaded from
 http://ahajournals.org by on January 23, 2020
BASIC SCIENCES - AL
Banerjee et al Evinacumab in HoFH With Range of LDLR Activity
Arterioscler Thromb Vasc Biol. 2019;39:2248–2260. DOI: 10.1161/ATVBAHA.119.313051 November 2019  2253
Functional In vitro Characterization of the 
Point Mutations and Frameshift LDLR Variants 
Present in the HoFH Patients
Next, in vitro LDLR activity of p.(Trp87Gly), p.(Cys681*), 
p.(Gln254Pro), p.(Ala627Profs*38), p.(Ser177Leu), 
p.(Gly335Val), and p.(Ser306Leu) LDLR variants was 
determined by flow cytometry in CHO-ldlA7 cells as 
described in the Materials and Methods section. The 
p.(Trp87*) and c.191-?_694+?del LDLR variants were 
used as internal controls for the assay. As shown in 
Figure 3A, expression of p.(Trp87Gly), p.(Gln254Pro), 
p.(Gly335Val), and p.(Ser306Leu) was similar to wt 
LDLR. As with the results obtained by Western blot (Fig-
ure 2), expression of the p.(Ser177Leu) diminished by 
≈40% compared with wt LDLR. As expected, expression 
Table. Baseline Characteristics, LDLR Genotypes, and LDL-C Levels With Evinacumab Treatment of Individual Patients With 
HoFH
Patient 
Number 
Baseline Characteristics LDL-C Level (mg/dL) LDLR Genotype*
Age, Y/
Sex
Premature 
Atheroscle-
rosis/ 
Xanthoma†
Background LLT at  
Screening PreLLT
Base-
line‡
LDL-C  
Value After  
Evinacumab 
(Peak % 
Reduction)§
State  
Mutational  
Category HGVS Nomenclature
ACMG Clas-
sification9
1 33/M Coronary and 
peripheral
Rosuvastatin 40 mg 561 516 253 (–50.9% 
at Week 10)
True homozy-
gous: defec-
tive/defective
c.[259T>G]; [259T>G]/p.[(Trp-
87Gly)]; [(Trp87Gly)]
VUS/VUS
Ezetimibe 10 mg∥
2 47/F Coronary and 
peripheral
Atorvastatin 80 mg 824 153 15 (–90.2% at 
Week 4)
True homozy-
gous: defec-
tive/defective
c.[259T>G]; [259T>G]/p.[(Trp-
87Gly)]; [(Trp87Gly)]
VUS/VUS
Ezetimibe 10 mg 
Lomitapide 20 mg
3 46/M Coronary and 
peripheral
Atorvastatin 80 mg 410¶ 297 179 (–39.7% 
at Week 6)
Compound 
heterozygous: 
null/defective
c.[-6211_67+3066del];[259T>G]/p.
[(Trp87Gly)];[?]
Pathogenic/
VUS
Ezetimibe 10 mg
Portacaval shunt
4 18/M Coronary Atorvastatin 80 mg 641 357 65 (–81.8% at 
Week 6)
Compound 
heterozygous: 
defective/null
c.[761A>C];[2043C>A]/p.
[(Gln254Pro)];[(Cys681*)]
VUS/patho-
genic
Ezetimibe 10 mg
Lipoprotein  
apheresis#
5 30/F No clinical 
event
Lipoprotein  
apheresis#,**
767 746 497 (–33.4% 
at Week 6)
True homozy-
gous: null/null
c.[1587-?-2140+?del];[1587-?-
2140+?del]
Pathogenic/
pathogenic
6 31/F Coronary and 
peripheral
Lomitapide 20 mg 870
 
736 298 (–59.5% 
at Week 8)
Compound 
heterozygous: 
null/null
c.[314-?_940+?del];[1878Adel]/p.
[(Pro105_Gly314delinsArg)];[(Ala62
7Profs*38)]
Pathogenic/
pathogenic
Lipoprotein  
apheresis#
7 37/M Coronary and 
peripheral
Atorvastatin 80 mg 840 312 149 (–52.2% 
at Week 8)
True homozy-
gous: null/null
c.[530C>T];[530C>T]/p.
[(Ser177Leu)];[(Ser177Leu)]
Pathogenic/
pathogenic
Ezetimibe 10 mg
Evolocumab 140 mg
8 41/M No coronary Atorvastatin 20 mg 696 152 67 (–55.8% at 
Week 6)
Compound 
heterozygous: 
null/defective
c.[621C>T];[1004G>T]/p.[(Gly207_
Cys231del)];[(Gly335Val)]
Likely patho-
genic/likely 
pathogenic
Ezetimibe 10 mg
Evolocumab 420 mg
9 40/F No coronary Rosuvastatin 20 mg 483 117 46 (–60.7% at 
Week 4)
Compound 
heterozygous: 
defective/
defective
c.[621C>T];[917C>T]/p.[(Gly207_
Cys231del)];[(Ser306Leu)]
Likely patho-
genic/likely 
pathogenic
Ezetimibe 10 mg
Evolocumab 140 mg
Arbitrary patient number shown in left-hand column for reference. AMCG indicates American College of Medical Genetics; F, female; FH, familial hypercholesterolemia; 
HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; HGVS, Human Genome Variation Society; LDL-C, low-density 
lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; LLT, lipid-lowering therapy; M, male; PCSK9, proprotein convertase subtilisin/kexin type 9; and VUS, vari-
ant of uncertain significance.
*The p.(Trp87Gly) (W66G) genotype, also called French Canadian Type 2 variant, is a known FH-causing receptor defective (non-null) missense mutation in exon 3. 
Homozygotes for this variant present a full HoFH phenotype. The >15 kb deletion in the promoter and exon 1, also called French Canadian Type 1, is a receptor nega-
tive mutation having been associated with <2% normal LDLR activity. p.(Cys681*) is null variant (a stop codon), whereas p.(Gln254Pro) is a defective (non-null) variant 
affecting the binding site.
†Combination of tendinous xanthoma, tuberous xanthoma, corneal arci, xanthelasmas.
‡Average of all measurements before the first study drug administration.
§Lowest LDL-C value achieved with evinacumab treatment.
∥Did not respond to PCSK9 monoclonal antibodies (<2% LDL-C decrease).
¶Prestatin and ezetimibe but postportacaval shunt value
#Lipoprotein apheresis was ceased >4 wk before baseline visit.
**This woman of childbearing potential had previously discontinued rosuvastatin 20 mg, ezetimibe 10 mg, and colestipol.
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Figure 1. LDLR (low-density lipoprotein receptor) activity in lymphocytes from 9 homozygous familial hypercholesterolemia 
(HoFH) patients before and after evinacumab treatment.  
LDLR expression (A); LDL binding (B); and LDL uptake (C). LDLR activity and expression was quantified by flow cytometry as described in 
the Materials and Methods section. The values represent the mean of 3 independent experiments; error bars represent ±SD. wt=wild-type 
(non-HoFH) control; c.[191-?_694+?del] and p.(Trp87*)=LDLR defective heterozygous patient controls (see Methods). (1;2) represents 
the mean±SD of patients 1 and 2 which carry the same LDLR variants; the lymphocytes from these 2 patients were analyzed independently. 
The sex of the patients 1 to 9 from which the lymphocytes were sourced is indicated in the Table. HoFH indicates homozygous familial 
hypercholesterolemia; LDL, low-density lipoprotein; and LDLR, low-density lipoprotein receptor. *P<0.001 comparing wt with each variant 
before and after treatment. No statistical significance was found when after treatment vs before treatment LDLR activity data (expression, 
binding, and uptake) of each variant was compared.
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of p.(Cys681*) and p.(Ala627Profs*38) at the cellular 
membrane surface was residual (Figure 3A).
As shown in Figure 3B, LDL-LDLR binding activi-
ties of p.(Trp87Gly), p.(Cys681*), p.(Gln254Pro), 
p.(Ala627Profs*38), and p.(Ser177Leu) were almost 
completely abolished as compared with wt. By con-
trast, the LDL-binding capacity of p.(Gly335Val) and 
p.(Ser306Leu) was partially impaired by ≈40% com-
pared with LDLR wt control (Figure 3B).
As shown in Figure 3C and in agreement with LDL-
LDLR binding results (Figure 3B), LDL internalization in 
CHO-ldlA7 cells expressing p.(Trp87Gly), p.(Cys681*), 
p.(Gln254Pro), p.(Ala627Profs*38), and p.(Ser177Leu) was 
highly diminished compared with wt. On the contrary, uptake 
activity of p.(Gly335Val) and p.(Ser306Leu) was significantly 
inhibited (by ≈40% compared with LDLR control) but to a 
lesser extent than the other variants studied (Figure 3C).
Analysis of LDLR Activity by Confocal 
Microscopy
LDLR variants found in the patients were classified by 
mutation type using confocal microscopy as described 
in Materials and Methods section. As shown in Fig-
ure 4A, the expressed LDLR variants p.(Cys681*) and 
p.(Ala627Profs*38) colocalize with calregulin (an 
Figure 2. Expression of wild-type LDLR and LDLR variants in Chinese hamster ovary-ldlA7 transfected cells.  
LDLR (low-density lipoprotein receptor) expression (upper) and GAPDH expression (A and C; lower); LDLR to GAPDH densitometric 
analysis (B and D). Cells were transfected with the corresponding plasmids carrying the LDLR mutations of interest and immunoblot analysis 
was performed, as described in Materials and Methods. The relative band intensity of mature LDLR protein expression was calculated as the 
ratio of 160 kDa LDLR band intensity to that of GAPDH. A representative experiment from 3 independently performed assays is shown in A. 
Levels of significance were determined by a 2-tailed Student t test, and a CI of >95% (P<0.05) was used to establish statistical significance. 
No statistically significant differences were found among LDLR expression for variants analyzed in A and B, but differences were significant for 
variants analyzed in C and D. wt indicates wild-type.
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endoplasmic reticulum-specific marker), and the recep-
tors do not reach the cellular membrane. Consequently, 
and as shown in Figure 4B and 4C, respectively, there 
is no significant LDL binding or uptake. Therefore, 
p.(Cys681*) and p.(Ala627Profs*38) LDLR variants are 
class 2 type mutations.
Next, we analyzed the class type mutation of 
p.(Trp87Gly), p.(Gln254Pro), p.(Ser177Leu), p.(Gly335Val), 
Figure 3. LDLR (low-density lipoprotein receptor) activity in Chinese hamster ovary-ldlA7-transfected cells.  
LDLR expression (A); LDL (low-density lipoprotein) binding (B); and LDL uptake (C). LDLR activity and expression was quantified by flow 
cytometry, as described in the Materials and Methods section. The values represent the mean of 3 independent experiments; error bars 
represent ±SD. wt indicates wild-type. *P<0.001 comparing wt with each variant.
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and p.(Ser306Leu) LDLR variants. As shown in Figure 5A, 
all are expressed in their mature form at the cellular sur-
face, similar to the wt LDLR. By contrast, LDL binding and 
uptake are almost completely abolished in p.(Trp87Gly), 
p.(Gln254Pro), and p.(Ser177Leu) LDLR compared 
with wt LDLR (Figure 5B and 5C). Interestingly, and 
confirming the results obtained by fluorescence-acti-
vated cell sorting, LDL binding and uptake activities of 
p.(Gly335Val) and p.(Ser306Leu) LDLR variants are 
diminished compared with wt LDLR but functional to a 
significant extent (Figure 5B and 5C). According to these 
results, p.(Trp87Gly), p.(Gln254Pro), p.(Ser177Leu), 
p.(Gly335Val), and p.(Ser306Leu) LDLR variants can be 
classified as type 3 mutations.
DISCUSSION
Results from the present study suggest that evinacumab 
treatment did not alter LDLR activity. LDLR variants stud-
ied in vitro had only residual expression and diminished 
LDL binding and uptake. Furthermore, LDL-C uptake was 
similarly low in lymphocytes taken before and after evi-
nacumab treatment. In comparison, patients with HoFH 
and the corresponding LDLR variants had LDL-C reduc-
tions ranging 50.9% to 90.2% following evinacumab 
treatment. The functionality of the LDLR variants in vitro 
did not show a pattern in relation to the magnitude of 
LDL-C reductions observed in the patients with the cor-
responding LDLR variant. For example, 2 patients had 
the same Trp87Gly variant but had LDL-C reductions of 
50.9% and 90.1%, respectively. The LDLR variants would 
be expected to have no relation to the LDL-C reduction if 
evinacumab has an LDLR-independent mechanism. The 
intrapatient variability in LDL-C reductions observed may 
be related to other factors that have not been investigated 
such as levels of ANGPTL3 and/or LPL. The mechanism 
leading to the large reduction in LDL-C with evinacumab 
is under investigation (Regeneron Pharmaceuticals, Inc). 
One possible mechanism may involve LPL as follows. 
ANGPTL3 inhibits LPL activity; inhibition of ANGPTL3 
with evinacumab may lead to increased LPL-mediated 
hydrolysis of triglycerides associated with very-low density 
lipoprotein and chylomicrons. The observed LDL-C reduc-
tions may, at least in part, result from lower secretion of 
very-low density lipoprotein, the precursor to LDL.28,29
A potential limitation of these analyses that used cells 
from patients before and after they were treated with 
evinacumab is that the patient cells were maintained in 
culture for 48 hours, without addition of the evinacumab. 
It is possible that the antibody effect could be missed 
because cells are not in constant contact with the anti-
body. However, overall, the results indicate that the LDLR 
variants were either not processed or expressed or had 
low activity compared with wt, yet, the patients had LDL-C 
reductions. This supports the overall conclusion that evi-
nacumab has an LDLR-independent mode of action.
In this study, we used the LDLR-deficient CHO cell 
line ldlA7 (CHO-ldlA7) for studying the LDLR variants 
instead of a hepatic cell line such as HepG2. CHO-
ldlA7 have been previously used in several LDLR func-
tional studies.30–32 An advantage of using CHO-ldlA7 
instead of a hepatic cell line such as HepG2 is that the 
CHO-ldlA7 cells do not express LDLR, making them an 
excellent model to study the effect of LDLR variants as 
they mimic the homozygous situation. Hepatic cell lines 
express wt LDLR, thus transfection with an LDLR vari-
ant would result in a heterozygous-like phenotype, mask-
ing the effect of the variant under analysis. This makes 
it more difficult to interpret the real effect of the LDLR 
variant under study. In addition, using the CHO-ldlA7 cell 
line allows both characterization and classification of the 
LDLR mutation class type. In a previous study, we used 
Figure 4. Class 2 type mutation assignment of variants found in homozygous familial hypercholesterolemia patients.  
LDLR (low-density lipoprotein receptor) expression and colocalization with calregulin in the endoplasmic reticulum (A); LDL (low-density 
lipoprotein)-LDLR binding activity (B); and LDL internalization activity (C). Confocal laser scanning microscopy was used to analyze LDLR 
activity, as described in the Materials and Methods section. wt indicates wild-type.
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a HepG2 cell line to characterize extracellular activity of 
PCSK9.33 In this case, we took advantage of the high 
LDLR expression in the HepG2 cells and added recom-
binant purified PCSK9 variants to the culture medium, 
then studied LDLR expression and LDL uptake. Also, 
we used HEK293 cells for transient transfection with 
PCSK9 variants because they do not express significant 
amounts of wt PCSK9.
Patients with HoFH who do not respond well to lipid-
lowering therapy have a poor prognosis, as survival has 
been shown to be determined by on-treatment serum 
cholesterol level.34,35 Novel treatment approaches are 
therefore vital. Although the recent LDLR-independent 
agents mipomersen and lomitapide may be of benefit 
in some patients, particularly those with LDLR-negative 
HoFH,13 they are associated with potentially harmful 
effects such as hepatotoxicity (elevated transaminases) 
and hepatic steatosis in adults;36,37 there are, as of yet, no 
efficacy or safety data in children.14
The evinacumab proof-of-concept study demon-
strated meaningful reductions in LDL-C on top of stan-
dard-of-care treatment in all 9 HoFH patients, including 3 
null/null patients, and LDL-C reductions were sustained 
for up to 2 months following the intravenous injection 
at Week 2.19 Evinacumab was also well tolerated at the 
doses given, including the 450 mg subcutaneous dose 
given to 2 patients at Weeks 12 to 15. While all patients 
reported at least 1 adverse event (including nausea and 
back pain in 4 patients each), there were no treatment 
discontinuations because of adverse events; there was 1 
serious adverse event (coronary artery disease because 
of underlying disease) in the main study period.19
Among the new treatments approved for lowering 
LDL-C are evolocumab and alirocumab, both monoclonal 
antibodies that prevent circulating PCSK9 from binding 
to the LDL receptor.38,39 Several lipid guidelines sug-
gest that these PCSK9 inhibitor antibodies may be suit-
able for individuals with FH or secondary prevention in 
patients with dyslipidemia in whom statins provide insuf-
ficient LDL-C control, due to either resistance to statin 
therapy or insufficient therapeutic success with statin 
with/without ezetimibe.40–42 The addition of either ali-
rocumab 150 mg every 2 weeks or evolocumab 140 mg 
monthly to statin therapy consistently resulted in an incre-
mental decrease in LDL-C levels of up to 60% in HeFH 
compared with placebo.43–45 However, PCSK9 inhibitor 
Figure 5. Class 3 type mutation assignment of variants found in homozygous familial hypercholesterolemia patients.  
LDLR (low-density lipoprotein receptor) expression at cellular membrane (A); LDL (low-density lipoprotein)-LDLR binding activity (B); and LDL 
internalization activity (C). Confocal laser scanning microscopy was used to analyze LDLR activity, as described in the Materials and Methods 
section. wt indicates wild-type.
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treatment resulted in a less pronounced LDL-C lowering 
efficacy (mean LDL-C reductions of ≈20% were reported) 
in HoFH patients with LDLR Class 2 and 3 mutations and 
with patients with mutations in ApoB100, which fails in 
LDLR recognition. Importantly, there is heterogeneity in 
the response to PCSK9 inhibitors among LDLR defective 
HoFH patients, as illustrated in the present study where a 
HoFH patient with LDLR class 3 mutation had an LDL-C 
reduction of <2%, suggesting several factors including 
baseline LDL-bound or receptor-bound PCSK9 concen-
trations may affect the LDL-C lowering effect of PCSK9 
inhibitor treatment in LDLR defective HoFH. By contrast, 
LDLR-negative patients were reported as having no or 
poor response to PCSK9 inhibitor treatment, as expected 
from the mechanism of action of this class of drugs.15–17 
Thus, new therapeutic strategies such as administration 
of evinacumab could be beneficial, especially for LDLR-
negative HoFH patients as shown in this study.
The functional and structural analysis reported here 
on these LDLR variants provides evidence that, in 
humans, inhibition of ANGPTL3 lowers LDL indepen-
dently of LDLR, and is useful for a more targeted treat-
ment of patients with significant defects in LDLR. The 
results also suggest that evinacumab may be effective 
in patients carrying Class 2 or 3 mutations with almost 
complete loss of LDL-binding capacity. This is important 
because the LDL-C-lowering capacity of other treat-
ments, such as statins and PCSK9 inhibitor antibodies, 
is restricted in such cases.
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